Oncoveda, Cancer Research Center, Medical Diagnostic Laboratories, L.L.C., Hamilton, NJ, 08690, USA.
Cancer Med. 2012 Aug;1(1):76-81. doi: 10.1002/cam4.15. Epub 2012 Jul 15.
Bladder cancer is one of the most common cancers in the United States. Numerous markers have been evaluated for suitability of bladder cancer detection and surveillance. However, few of them are acceptable as a routine tool. Therefore, there exists a continuing need for an assay that detects the presence of bladder cancer in humans. It would be advantageous to develop an assay with a protein that is associated with the development of bladder cancer. We have identified the cancerous inhibitor of PP2A (CIP2A) protein as a novel bladder cancer biomarker. In this study, Western blot analysis was used to assess the expression level of CIP2A protein in bladder cancer cell lines and bladder cancer patient tissues (n = 43). Our studies indicated CIP2A protein was abundantly expressed in bladder cancer cell lines but not in nontumor epithelial cell lines. Furthermore, CIP2A was specifically expressed in transitional cell carcinoma (TCC) of the bladder tumor tissues but not in adjacent nontumor bladder tissue. Our data showed that CIP2A protein detection in high-grade TCC tissues had a sensitivity of 65%, which is 3.4-fold higher than that seen in low-grade TCC tissues (19%). The level of CIP2A protein expression increased with the stage of disease (12%, 27%, 67%, and 100% for pTa, pT1, pT2, and pT3 tumor, respectively). In conclusion, our studies suggest that CIP2A protein is specifically expressed in human bladder tumors. CIP2A is preferentially expressed in high-grade and high-stage TCC tumors, which are high-risk and invasive tumors. Our studies reported here support the role of CIP2A in bladder cancer progression and its usefulness for the surveillance of recurrence or progression of human bladder cancer.
膀胱癌是美国最常见的癌症之一。已经评估了许多标记物来评估其用于膀胱癌检测和监测的适用性。然而，很少有标记物被接受为常规工具。因此，仍然需要一种能够检测人类膀胱癌的检测方法。开发一种与膀胱癌发生相关的蛋白质检测方法将是有利的。我们已经确定了蛋白磷酸酶 2A 的致癌抑制剂（CIP2A）蛋白是一种新的膀胱癌生物标志物。在这项研究中，使用 Western blot 分析评估了 CIP2A 蛋白在膀胱癌细胞系和膀胱癌患者组织（n=43）中的表达水平。我们的研究表明，CIP2A 蛋白在膀胱癌细胞系中大量表达，但在非肿瘤上皮细胞系中不表达。此外，CIP2A 特异性表达于膀胱肿瘤组织的移行细胞癌（TCC）中，而不是相邻的非肿瘤膀胱组织中。我们的数据表明，在高级别 TCC 组织中检测到 CIP2A 蛋白的灵敏度为 65%，比在低级别 TCC 组织中（19%）高 3.4 倍。CIP2A 蛋白表达水平随疾病分期而增加（分别为 pTa、pT1、pT2 和 pT3 肿瘤的 12%、27%、67%和 100%）。总之，我们的研究表明 CIP2A 蛋白特异性表达于人类膀胱癌。CIP2A 优先在高级别和高分期的 TCC 肿瘤中表达，这些肿瘤是高风险和侵袭性肿瘤。我们在这里报告的研究支持 CIP2A 在膀胱癌进展中的作用及其在监测人类膀胱癌复发或进展中的用途。
